Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by LENZ, O.
Right arrow Articles by STETLER-STEVENSON, W. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by LENZ, O.
Right arrow Articles by STETLER-STEVENSON, W. G.
J Am Soc Nephrol 11:574-581, 2000
© 2000 American Society of Nephrology

REVIEW

Matrix Metalloproteinases in Renal Development and Disease

OLIVER LENZ*, SHARON J. ELLIOT* and WILLIAM G. STETLER-STEVENSON{dagger}

* Renal Cell Biology Laboratory, University of Miami School of Medicine, Miami, Florida
{dagger} Extracellular Matrix Pathology Section, DCS, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

Correspondence to Dr. William G. Stetler-Stevenson, Extracellular Matrix Pathology Section, LP/DCBDC/NIC/NIH, Building 10, Room 2A33, 9000 Rockville, Pike, Bethesda, MD 20892. Phone: 301-496-2687; Fax: 301-402-2628; E-mail: sstevenw{at}mail.nih.gov

Remodeling of extracellular matrix (ECM) is an important physiologic feature of normal growth and development. Many diseases have been associated with an imbalance of ECM synthesis and degradation, which may result in an accumulation of ECM molecules (1). In the kidney, these processes can lead to interstitial fibrosis, which has been reviewed elsewhere (2,3,4), and glomerulosclerosis (5). Progressive glomerulosclerosis leading to end-stage renal failure is a complication of a variety of diseases, such as diabetes mellitus, glomerulonephritis, focal sclerosis, chronic transplant rejection, or obstruction (6,7,8,9,10,11). Although many studies have tried to elucidate the pathogenesis, the exact underlying mechanisms are still not completely understood. While increased synthesis of ECM certainly plays an important role, recent studies have focused on the role of degradative systems. The major physiologic regulators of ECM degradation in the glomerulus are matrix metalloproteinases (MMP) (12). Both glomerular disease and normal renal development are characterized by a high rate of ECM turnover. Since the underlying mechanisms may follow similar patterns, we will discuss the role of MMP in chronic glomerular disease and normal renal development, and we will highlight implications of experimental findings for human renal disease.

Structure and Function of MMP

MMP are a large family of zinc-dependent matrix-degrading enzymes, which include the interstitial collagenases, stromelysins, gelatinases, elastases, and secreted, as well as membrane-type, RXKR containing MMP (13,14,15,16,17,18) (Table 1). They have been implicated in invasive cell behavior (18, 19), embryonic development (20,21,22), interstitial fibrosis (23), and glomerulosclerosis (24, 25). MMP share several structural and functional properties, which include pre/pro-peptide (26), hinge, hemopexin-like (except MMP-7), and catalytic zinc-binding domains (27, 28) (Figure 1). They synergistically degrade a broad range of ECM compounds. Of the currently known MMP, MMP-1, MMP-13, MMP-3, MMP-2, MMP-9, and MT-1-MMP have been extensively studied in the kidney. Four members in this group of collagenases, MMP-1, MMP-2, MMP-8 and MMP-13, share the ability to degrade fibrillar collagens (29,30,31). The resulting fragments denature spontaneously under physiologic temperatures, which then can be further degraded by other proteases.


View this table:
[in this window]
[in a new window]

  		Table 1. The matrix metalloproteinase (MMP) family: current nomenclature and substrate specificity
 


View larger version (39K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Figure 1 . Domain structure of the matrix metalloproteinases (MMP). (A) Simplified schematic of the minimal domain structure of the MMP. Most MMP have the same basic domain structure consisting of signal (pre-), pro-, and catalytic domains. The prodomain contains a highly conserved sequence (shown in single letter amino acid code) that is responsible for maintaining the latency of the proenzyme. (B) Additional domains observed in various members of the MMP family. The F denotes location of the furin RXKR cleavage site of MMP-11 and the membrane-type MMP. The FBN represents the type II repeats of fibronectin found in the gelatinases. C represents a type V collagenlike sequence found in MMP-9. H denotes the flexible hinge region that usually separates the catalytic and hemopexin-like (PEX) domains. TM represents the transmembrane domain characteristic of the membrane-type (MT)-MMP.

 

There are two gelatinases, MMP-2 and MMP-9. While sharing the ability to degrade both basement membrane collagens and gelatins, their substrate specificity is not identical. MMP-2 degrades fibronectin and laminin, and has significantly less activity against types IV and V collagen than MMP-9 (32,33,34). They also vary greatly in their promoter structure, and thus in their expression pattern (35). MMP-2 and MMP-9 are also unique in that they form proenzyme complexes with their endogenous inhibitors tissue inhibitor of metalloproteinase-2 (TIMP-2) and TIMP-1, respectively (36,37,38,39), which have been shown to be expressed in human glomeruli (40). Although the roles of these complex formations in ECM turnover have not been completely elucidated, they may at least in part account for the selective inhibition of MMP-2 by TIMP-2. Other possible roles of complex formation include regulation of cell surface localization of MMP via integrin receptors such as {alpha}VB3 (41) (vide infra), mediation of the cell surface activation of MMP by MT-1-MMP (26, 42, 43), as well as regulation of MMP (44) and/or TIMP (45, 46) cell growth-modulating activity. However, the growth-regulating activity of MMP and TIMP in renal development and disease has not been directly demonstrated.

Stromelysin-1 and stromelysin-2 share almost identical substrate specificity, but, like the gelatinases, are differentially regulated. With the exception of human T lymphocytes, stromelysin-2 is constitutively expressed at low levels or is absent, while stromelysin-1 can be induced by the cytokines interleukin-1ß and tumor necrosis factor-{alpha}, the growth factors epidermal growth factor and platelet-derived growth factor, and phorbol esters, and inhibited by transforming growth factor-ß (TGF-ß) and retinoic acid (35).

Members of the RXKR group share the recognition motif that consists of the highly basic sequence of amino acid residues arginine,arginine/glutamine,lysine,arginine. This sequence of residues is recognized by the Golgi-associated proteinase furin, which has been implicated in the activation process of these MMP (14, 43). The membrane-type MMP contain a transmembrane COOH-terminal end, and they have been shown to play a role in the regulation of proenzyme processing of the pro-MMP-2/TIMP-2 complex (42, 43).

MMP in Glomerular Disease

Mechanisms of Action
The major physiologic regulators of ECM degradation in the glomerulus are MMP (12). A balance between ECM synthesis and degradation is a prerequisite for maintaining the structural and functional integrity of the glomerulus. Thus, changes in MMP expression or activity will directly translate into altered ECM turnover, which may lead to glomerular scarring and a decline in renal function.

Many forms of glomerular disease are characterized by a change in cellularity, which in turn may affect ECM composition and turnover. MMP have been shown to influence the behavior of glomerular cells either directly or via the generation of ECM cleavage products (44, 47).

MMP may also indirectly influence ECM turnover via the regulation of certain growth factors. Recently, regulation of growth factor activity by MMP has been observed in MMP-9-deficient mice, which exhibit abnormal growth plate vascularization and ossification (48), and binding proteins for insulin-like growth factor-1 have been identified as substrates of MMP (49).

Finally, in diseases with altered matrix composition, such as Alport disease, an increased susceptibility of the basement membrane to degradation by MMP has been postulated to cause glomerular damage (50). These findings illustrate that MMP are involved at several levels of ECM turnover, and thus play a crucial role in maintaining the balance between ECM synthesis and degradation.

MMP in Noninflammatory Glomerular Disease

The role of MMP and their endogenous inhibitors in the development of glomerular damage has been studied in a variety of experimental conditions (Figure 2). In general terms, a downregulation of MMP has been associated with progression in noninflammatory diseases such as hypertensive glomerulosclerosis (51, 52), growth hormone excess (25, 53), hydronephrosis (54,55,56), hypercholesterolemia (57), heroin nephropathy (58), cyclosporine nephrotoxicity (59), or sex-related changes in the aging kidney (60). In this review, we chose diabetic nephropathy as one example to illustrate the link between progressive glomerulosclerosis and MMP expression.



View larger version (49K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Figure 2 . Schematic overview of glomerulosclerosis disease progression. This diagram compares and contrasts the disease process associated with both inflammatory mechanisms and noninflammatory mechanisms that can result in glomerulosclerosis.

 

Diabetic nephropathy has been studied extensively, as it is the leading cause of end-stage renal disease in the United States, Japan, and Europe (61,62,63,64). Histologically, glomerular hypertrophy, glomerular basement membrane thickening, and mesangial expansion characterize diabetic nephropathy (65, 66). In vitro, studies of the effect of high ambient glucose on ECM turnover revealed an increased expression of matrix molecules, while the activity of MMP, namely MMP-2 and MMP-9, were decreased in mesangial cells (67,68,69). These findings were confirmed in streptozotocin (STZ)-treated diabetic rats, in which not only a downregulation of MMP (70,71,72), but also an upregulation of TIMP-1 was observed (24, 73). The latter could accentuate the imbalance between matrix synthesis and degradation. Kidney biopsies from patients with diabetic nephropathy showed an inverse correlation between MMP-3/TIMP-1 mRNA levels and matrix accumulation (74). In addition, a marked decrease in MMP-2 mRNA expression was detected in glomeruli of diabetic patients (75). Taken together, these findings suggest that matrix accumulation in diabetic nephropathy is due to increased matrix synthesis and decreased degradation, and that MMP may play a pivotal role.

The mechanisms underlying this process have not yet been completely elucidated. Both circulating and/or locally synthesized growth factors and cytokines modulate MMP expression in diabetic nephropathy. We have shown that insulin-like growth factor-1 decreases MMP expression, and thus down-regulates collagen degradation in mesangial cells derived from diabetic NOD mice (76, 77).

The role of TGF-ß in the pathogenesis of ECM accumulation remains controversial. TGF-ß has been shown to upregulate MMP-2 (78). In a recent study in db/db mice, TGF-ß1 levels in diabetic kidney cortex have been shown to be decreased (79). It is not clear how this finding relates to previous observations of increased TGF-ß levels in diabetic nephropathy (80, 81). The role of TGF-ß1 and TGF-ß-neutralizing proteoglycans (82) in the pathogenesis of diabetic nephropathy may have to be reevaluated (83).

Oxidative stress (84) contributes to matrix accumulation either directly due to inhibition of MMP-2 (85), or by inducing a cytokine response (86, 87).

The detrimental role of hyperglycemia itself has been established by the observation that glycemic control can prevent or at least slow progression of diabetic nephropathy in a number of patients (88). This may be explained in part by the observation that decreased gelatinase activity in STZ-treated rats can be restored by insulin treatment (89). Glucose levels also may indirectly influence matrix turnover, since glycated fetal bovine serum was shown to decrease matrix turnover by glomerular epithelial cells (90), and glycated type IV collagen has been shown to be less degradable by MMP-3 and MMP-9 (91). The need for tight glycemic control in diabetes is emphasized by a recent study showing that pancreas transplantation can reverse glomerular lesions in patients with diabetic nephropathy (92), even though other intrinsic factors that have not yet been identified may play a role in this setting.

In addition, the genetic background may have a strong influence on the incidence of renal complications in diabetes (93), and the level of MMP expression may be one of the determinants. STZ-treated Sprague Dawley rats developed diabetic nephropathy and exhibited decreased metalloproteinase levels. These nephropathy changes and altered MMP expression were not observed in spontaneously diabetic BB/DP and STZ-treated BB/DR rats (71). Thus, MMP may be useful to identify patients at risk for developing progressive renal failure.

In summary, progressive glomerulosclerosis in a variety of diseases, such as diabetic nephropathy, is characterized by a profound shift in ECM turnover toward increased matrix accumulation, leading to mesangial matrix expansion, decrease in filtration area, and ultimately end-stage renal failure. Glomerular MMP levels could determine the slope of progression and the degree of glomerular scarring. Experimental data suggest that this is a general theme in a variety of primarily noninflammatory diseases associated with glomerulosclerosis.

MMP in Glomerulonephritis

In inflammatory glomerular diseases, the findings are quite different with regard to MMP expression. Increased levels of MMP are generally associated with disease activity and influx of inflammatory cells, and both the level and the duration of MMP elevation determine the extent of glomerular damage.

In mice with experimental lupus nephritis, MMP-1, -2, and -3 were shown to be increased (94), while an elevation of MMP-2 and MMP-9 was observed in both anti-Thy1.1 nephritic rats (78, 95, 96) and rats with passive Heymann nephritis (97). Increased MMP expression in Thy1.1 nephritis may be partly mediated by growth factors released by invading activated neutrophils and macrophages (98, 99). Another possibility is a permanent change in the phenotype of mesangial cells due to the inflammatory process, since mesangial cells isolated from nephritic animals maintain their altered phenotype in vitro (100). Data from human studies also show that elevated MMP levels are associated with a highly active inflammatory response associated with glomerular damage. Elevated levels of MMP were found in various forms of glomerulonephritis in Japanese patients (101, 102).

Taken together, experimental data and findings from human studies suggest that elevated glomerular MMP expression contributes to the disease process, and that increased MMP activity correlates with structural glomerular damage. Unlike experimental Thy1.1 nephritis in rats, which resolves spontaneously when only one dose is given, many forms of glomerulonephritis in humans progress to end-stage renal failure. In experimental nephritis, both dietary measures (103) and MMP inhibition attenuate glomerular lesions (96), suggesting a role for MMP inhibitors in the treatment of acute glomerulonephritis (96, 104, 105). Thus, future therapeutic approaches may include targeting selected members of the MMP family and/or their endogenous inhibitors. Additional studies will be needed, however, to establish the efficacy of this measure in preventing progressive renal failure.

The most common form of nephrotic syndrome in adults is membranous glomerulonephritis. A role for MMP in the alteration of basement membrane permeability has been postulated by an uncontrolled study in patients with membranous glomerulonephritis, which revealed elevated levels of TGF-ß and collagenase activity in the urine (106). This notion is supported by the finding that MMP-9 expression by podocytes is increased in a model of membranous nephropathy (97). In a mouse model mimicking focal segmental glomerulosclerosis, characterized by the lack of Mpv17 gene expression leading to persistently high levels of MMP-2, the authors found foot process flattening, heavy proteinuria, and ultimately severe glomerulosclerosis (107,108,109). However, the glomerular expression pattern of MMP and TIMP has not yet been studied in detail. In addition, the overexpression of MMP-2 occurs from the first days of life on, which makes it difficult to correlate this model with human disease. Future approaches may use conditional knockouts or the conditional overexpression of MMP and/or TIMP to further define the role of MMP in glomerulonephritis.

MMP in Renal Development

Both renal disease and kidney development are characterized by a high rate of ECM turnover, which may indicate that similar mechanisms are at work. During renal development, a constant remodeling of ECM is required to allow invasion and branching of the ureteric bud in the metanephric mesenchyme, which suggests a role for matrix-degrading enzymes. Nephrogenesis is characterized by a complex interaction between epithelium and mesenchyme (21, 110,111,112). Since a differential spatiotemporal expression of MMP and TIMP has been shown in the development of other branching organs (113), a similar role of MMP and TIMP in renal organogenesis has been proposed (114, 115). In the developing kidney, MMP-2 mRNA expression is limited to the mesenchyme. MMP-2 protein, however, has been found in immature nephron structures undergoing epithelial differentiation, where it colocalizes with MT-1-MMP, TIMP-2, and TIMP-3 (116, 117). This has given rise to the hypothesis that the interaction between MMP-2, MT-1-MMP, and TIMP-2 may be crucial for the interaction between mesenchyme and epithelium, facilitating branching of the developing ureteric bud. This hypothesis is supported by the fact that treatment with MT-1-MMP antisense oligode-oxynucleotides inhibits the branching process (118), and that the expression of MMP-2 and MT-1-MMP is regulated in a temporal manner (117). A recent study showed that inhibition of MMP-2 by TIMP-2 strongly reduced the number of branches in the rat metanephros (119). It is unclear why only treatment with an anti-MMP-9 antibody prevented ureteric bud branching in 11-d mouse kidneys, while an anti-MMP-2 antibody did not have a deleterious effect (22). Analysis of the kidney morphology in MMP-2- and MMP-9-deficient mice may help to clarify the role of the two gelatinases in renal organogenesis (48, 120). However, other MMP, such as MMP-1, have also been shown to play a role in the branching morphogenesis and may be modulated by growth factors such as TGF-ß (121). Thus, MMP seem to play an important role in epithelium—mesenchyme interactions in renal development and the determination of nephron number. A decrease in the total number of nephrons has been postulated to play a role in the development of chronic renal disease later in life (122,123,124). Conditions known to reduce nephron number, such as malnutrition (125) or gentamicin nephrotoxicity (126), may be mediated by decreased fetal MMP expression.

In summary, the tight regulation of the MMP system is essential for normal renal development. Although it may be possible to counteract MMP dysregulation pharmacologically, additional studies will be needed to elucidate the regulation of MMP expression in the developing kidney under normal and pathologic conditions, so that the appropriate time and type of intervention can be determined.

Conclusion

Mounting evidence indicates that MMP play a pivotal role in the regulation of ECM turnover in the glomerulus. Various forms of glomerular disease are characterized by a profound shift in the balance between matrix synthesis and degradation. While in the scarring process the balance is tilted toward increased synthesis, excess degradative activity promotes glomerular destruction in inflammatory diseases. Recent studies show that MMP are also intricately involved in renal organogenesis. Disturbances in kidney development may in part be linked to a dysregulation of MMP expression during embryogenesis and may have profound implications for renal disease in adult life. Future studies to better understand the underlying genetic and molecular regulation may lead to pharmacologic manipulations of MMP activity or expression to treat and/or prevent glomerular diseases.

Acknowledgments

Acknowledgments

This work was supported in part by National Institutes of Health Grant 1 RO1 AG1717001 to Dr. Liliane J. Striker. We thank Dr. Liliane J. Striker and Dr. Gary E. Striker (Renal Cell Biology Laboratory, University of Miami School of Medicine) for their generous support and valuable suggestions. We thank the fellows in the Renal Cell Biology Laboratory, University of Miami School of Medicine, Dr. Alessia Fornoni, Dr. Mylene Potier, and Dr. Ivan Tack, for critically reading the manuscript and providing useful comments.

Footnotes

American Society of Nephrology

References

  1. Arthur MJ: Fibrosis and altered matrix degradation.Digestion 59:376 -380, 1998[Medline]
  2. Norman JT, Lewis MP: Matrix metalloproteinases (MMPs) in renal fibrosis. Kidney Int Suppl 54:S61 -S63, 1996[Medline]
  3. Heidland A, Sebekova K, Paczek L, Teschner M, Dammrich J, Gaciong Z: Renal fibrosis: Role of impaired proteolysis and potential therapeutic strategies. Kidney Int Suppl 62:S32 -S35, 1997[Medline]
  4. El Nahas AM, Muchaneta-Kubara EC, Essawy M, Soylemezoglu O: Renal fibrosis: Insights into pathogenesis and treatment. Int J Biochem Cell Biol 29: 55-62,1997[Medline]
  5. He C, Zalups RK, Henderson DA, Striker GE, Striker LJ: Molecular analysis of spontaneous glomerulosclerosis in Os/+ mice, a model with reduced nephron mass. Am J Physiol 269:F266 -F273, 1995[Abstract/Free Full Text]
  6. Abrass CK, Peterson CV, Raugi GJ: Phenotypic expression of collagen types in mesangial matrix of diabetic and nondiabetic rats.Diabetes 37:1695 -1702, 1988[Abstract]
  7. Schnaper HW, Robson A: Nephrotic syndrome: Minimal change disease, focal glomerulosclerosis, and related disorders. In: Diseases of the Kidney, 5th Ed., edited by Schrier CW, Gottschalk CW, Boston, Little, Brown & Co., 1992, pp1731 -1784
  8. Warshaw BL, Edelbrock HH, Ettenger RB, Malekzadeh MH, Pennisi AJ, Uittenbogaart CH, Fine RN: Progression to end-stage renal disease in children with obstructive uropathy. J Pediatr100 : 183-187,1982[Medline]
  9. Morel-Maroger SL, Killen PD, Chi E, Striker GE: The composition of glomerulosclerosis. I. Studies in focal sclerosis, crescentic glomerulonephritis, and membranoproliferative glomerulonephritis. Lab Invest 51: 181-192,1984[Medline]
  10. Thoenes W, Rumpelt HJ: The obsolescent renal glomerulus—collapse, sclerosis, hyalinosis, fibrosis. A light- and electron microscopical study on human biopsies. Virchows Arch A Pathol Anat Histol 377: 1-15,1977[Medline]
  11. Jeong HJ, Kim YS, Oh CK, Park K, Choi IJ: Immunologic and nonimmunologic contributors to glomerular segmental sclerosis in renal transplantation. Transplant Proc 28:1224 -1225, 1996[Medline]
  12. Woessner JF Jr: Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 5:2145 -2154, 1991[Abstract]
  13. Stetler-Stevenson WG: Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix. Am J Pathol148 : 1345-1350,1996[Medline]
  14. Puente XS, Pendas AM, Llano E, Velasco G, Lopez-Otin C: Molecular cloning of a novel membrane-type matrix metalloproteinase from a human breast carcinoma. Cancer Res 56:944 -949, 1996[Abstract/Free Full Text]
  15. Will H, Hinzmann B: cDNA sequence and mRNA tissue distribution of a novel human matrix metalloproteinase with a potential transmembrane segment.Eur J Biochem 231:602 -608, 1995[Medline]
  16. Takino T, Sato H, Yamamoto E, Seiki M: Cloning of a human gene potentially encoding a novel matrix metalloproteinase having a C-terminal transmembrane domain. Gene 155:293 -298, 1995[Medline]
  17. Takino T, Sato H, Shinagawa A, Seiki M: Identification of the second membrane-type matrix metalloproteinase (MT-MMP-2) gene from a human placenta cDNA library: MT-MMPs form a unique membrane-type subclass in the MMP family. J Biol Chem 270:23013 -23020, 1995[Abstract/Free Full Text]
  18. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M: A matrix metalloproteinase expressed on the surface of invasive tumor cells.Nature 370:61 -65, 1994[Medline]
  19. Yu AE, Hewitt RE, Connor EW, Stetler-Stevenson WG: Matrix metalloproteinases: Novel targets for directed cancer therapy. Drugs Aging 11: 229-244,1997[Medline]
  20. Alexander CM, Hansell EJ, Behrendtsen O, Flannery ML, Kishnani NS, Hawkes SP, Werb Z: Expression and function of matrix metalloproteinases and their inhibitors at the maternal-embryonic boundary during mouse embryo implantation. Development 122:1723 -1736, 1996[Abstract]
  21. Brenner CA, Adler RR, Rappolee DA, Pedersen RA, Werb Z: Genes for extracellular-matrix-degrading metalloproteinases and their inhibitor, TIMP, are expressed during early mammalian development. Genes Dev3 : 848-859,1989[Abstract/Free Full Text]
  22. Lelongt B, Trugnan G, Murphy G, Ronco PM: Matrix metalloproteinases MMP2 and MMP9 are produced in early stages of kidney morphogenesis but only MMP9 is required for renal organogenesis in vitro. J Cell Biol136 : 1363-1373,1997[Abstract/Free Full Text]
  23. Norman JT, Gatti L, Wilson PD, Lewis M: Matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases expression by tubular epithelia and interstitial fibroblasts in the normal kidney and in fibrosis.Exp Nephrol 3:88 -89, 1995[Medline]
  24. Schaefer L, Han X, August C, Matzkies F, Lorenz T, Schaefer RM: Differential regulation of glomerular gelatinase B (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1) in obese Zucker rats.Diabetologia 40:1035 -1043, 1997[Medline]
  25. Jacot TA, Striker GE, Stetler-Stevenson M, Striker LJ: Mesangial cells from transgenic mice with progressive glomerulosclerosis exhibit stable, phenotypic changes including undetectable MMP-9 and increased type IV collagen. Lab Invest 75:791 -799, 1996[Medline]
  26. Nagase H: Activation mechanisms of matrix metalloproteinases.Biol Chem 378:151 -160, 1997[Medline]
  27. Massova I, Kotra LP, Fridman R, Mobashery S: Matrix metalloproteinases: Structures, evolution, and diversification. FASEB J 12: 1075-1095,1998[Abstract/Free Full Text]
  28. Bode W, Gomis-Ruth FX, Huber R, Zwilling R, Stocker W: Structure of astacin and implications for activation of astacins and zinc-ligation of collagenases. Nature 358:164 -167, 1992[Medline]
  29. Mallya SK, Mookhtiar KA, Gao Y, Brew K, Dioszegi M, Birkedal-Hansen H, Van Wart HE: Characterization of 58-kilodalton human neutrophil collagenase: Comparison with human fibroblast collagenase.Biochemistry 29:10628 -10634, 1990[Medline]
  30. Mitchell PG, Magna HA, Reeves LM, Lopresti-Morrow LL, Yocum SA, Rosner PJ, Geoghegan KF, Hambor JE: Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. J Clin Invest97 : 761-768,1996[Medline]
  31. Hasty KA, Hibbs MS, Kang AH, Mainardi CL: Heterogeneity among human collagenases demonstrated by monoclonal antibody that selectively recognizes and inhibits human neutrophil collagenase. J Exp Med159 : 1455-1463,1984[Abstract/Free Full Text]
  32. Okada Y, Gonoji Y, Naka K, Tomita K, Nakanishi I, Iwata K, Yamashita K, Hayakawa T: Matrix metalloproteinase 9 (92-kDa gelatinase/type IV collagenase) from HT 1080 human fibrosarcoma cells: Purification and activation of the precursor and enzymic properties. J Biol Chem267 : 21712-21719,1992[Abstract/Free Full Text]
  33. Morodomi T, Ogata Y, Sasaguri Y, Morimatsu M, Nagase H: Purification and characterization of matrix metalloproteinase 9 from U937 monocytic leukaemia and HT1080 fibrosarcoma cells. Biochem J285 : 603-611,1992
  34. Olson MW, Toth M, Gervasi DC, Sado Y, Ninomiya Y, Fridman R: High affinity binding of latent matrix metalloproteinase-9 to the alpha2(IV) chain of collagen IV. J Biol Chem 273:10672 -10681, 1998[Abstract/Free Full Text]
  35. Borden P, Heller RA: Transcriptional control of matrix metalloproteinases and the tissue inhibitors of matrix metalloproteinases.Crit Rev Eukaryotic Gene Expression 7:159 -178, 1997[Medline]
  36. Imai K, Ohuchi E, Aoki T, Nomura H, Fujii Y, Sato H, Seiki M, Okada Y: Membrane-type matrix metalloproteinase 1 is a gelatinolytic enzyme and is secreted in a complex with tissue inhibitor of metalloproteinases 2.Cancer Res 56:2707 -2710, 1996[Abstract/Free Full Text]
  37. Stetler-Stevenson WG, Krutzsch HC, Liotta LA: Tissue inhibitor of metalloproteinase (TIMP-2): A new member of the metalloproteinase inhibitor family. J Biol Chem 264:17374 -17378, 1989[Abstract/Free Full Text]
  38. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI: Mechanism of cell surface activation of 72-kDa type IV collagenase: Isolation of the activated form of the membrane metalloprotease. J Biol Chem 270: 5331-5338,1995[Abstract/Free Full Text]
  39. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP: Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions.Eur J Cell Biol 74:111 -122, 1997[Medline]
  40. Carome MA, Striker LJ, Peten EP, Moore J, Yang CW, Stetler-Stevenson WG, Striker GE: Human glomeruli express TIMP-1 mRNA and TIMP-2 protein and mRNA. Am J Physiol264 : F923-F929,1993[Abstract/Free Full Text]
  41. Brooks PC, Stromblad S, Sanders LC, von Schalscha TL, Aimes RT, Stetler-Stevenson WG, Quigley JP, Cheresh DA: Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 85:683 -693, 1996[Medline]
  42. Kinoshita T, Sato H, Takino T, Itoh M, Akizawa T, Seiki M: Processing of a precursor of 72-kilodalton type IV collagenase/gelatinase A by a recombinant membrane-type 1 matrix metalloproteinase. Cancer Res 56: 2535-2538,1996[Abstract/Free Full Text]
  43. Pei D, Weiss SJ: Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature 375:244 -247, 1995[Medline]
  44. Turck J, Pollock AS, Lovett DH: Gelatinase A is a glomerular mesangial cell growth and differentiation factor. Kidney Int51 : 1397-1400,1997[Medline]
  45. Guedez L, Stetler-Stevenson WG, Wolff L, Wang J, Fukushima P, Mansoor A, Stetler-Stevenson M: In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. J Clin Invest 102: 2002-2010,1998[Medline]
  46. Corcoran ML, Stetler-Stevenson WG: Tissue inhibitor of metalloproteinase-2 stimulates fibroblast proliferation via a cAMP-dependent mechanism. J Biol Chem 270:13453 -13459, 1995[Abstract/Free Full Text]
  47. Giannelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson WG, Quaranta V: Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science 277:225 -228, 1997[Abstract/Free Full Text]
  48. Vu TH, Shipley JM, Bergers G, Berger JE, Helms JA, Hanahan D, Shapiro SD, Senior RM, Werb Z: MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes.Cell 93:411 -422, 1998[Medline]
  49. Fowlkes JL, Thrailkill KM, Serra DM, Suzuki K, Nagase H: Matrix metalloproteinases as insulin-like growth factor binding protein-degrading proteinases. Prog Growth Factor Res 6:255 -263, 1995[Medline]
  50. Kalluri R, Shield CF, Todd P, Hudson BG, Neilson EG: Isoform switching of type IV collagen is developmentally arrested in X-linked Alport syndrome leading to increased susceptibility of renal basement membranes to endoproteolysis. J Clin Invest 99:2470 -2478, 1997[Medline]
  51. Singhal PC, Sagar S, Garg P: Simulated glomerular pressure modulates mesangial cell 72 kDa metalloproteinase activity. Connect Tissue Res 33:257 -263, 1996[Medline]
  52. Trachtman H, Futterweit S, Garg P, Reddy K, Singhal PC: Nitric oxide stimulates the activity of a 72-kDa neutral matrix metalloproteinase in cultured rat mesangial cells. Biochem Biophys Res Commun218 : 704-708,1996[Medline]
  53. He CJ, Yang CW, Peten EP, Liu ZH, Patel A, Striker LJ, Striker GE: Collagen and collagenase mRNAs in normal and sclerotic glomeruli: Predictors of progression and response to therapy. Kidney Int Suppl49 : S39-S43,1995[Medline]
  54. Engelmyer E, van Goor H, Edwards DR, Diamond JR: Differential mRNA expression of renal cortical tissue inhibitor of metalloproteinase-1, -2, and -3 in experimental hydronephrosis. J Am Soc Nephrol5 : 1675-1683,1995[Abstract]
  55. Sharma AK, Mauer SM, Kim Y, Michael AF: Altered expression of matrix metalloproteinase-2, TIMP, and TIMP-2 in obstructive nephropathy.J Lab Clin Med 125:754 -761, 1995[Medline]
  56. Diamond JR: Macrophages and progressive renal disease in experimental hydronephrosis. Am J Kidney Dis26 : 133-140,1995[Medline]
  57. Guijarro C, Kasiske BL, Kim Y, O'Donnell MP, Lee HS, Keane WF: Early glomerular changes in rats with dietary-induced hypercholesterolemia.Am J Kidney Dis 26:152 -161, 1995[Medline]
  58. Sagar S, Sorbi D, Arbeit LA, Singhal PC: Morphine modulates 72-kDa matrix metalloproteinase. Am J Physiol267 : F654-F659,1994[Abstract/Free Full Text]
  59. Duymelinck C, Deng JT, Dauwe SE, De Broe ME, Verpooten GA: Inhibition of the matrix metalloproteinase system in a rat model of chronic cyclosporine nephropathy. Kidney Int 54:804 -818, 1998[Medline]
  60. Reckelhoff JF, Baylis C: Glomerular metalloprotease activity in the aging rat kidney: Inverse correlation with injury. J Am Soc Nephrol 3: 1835-1838,1993[Abstract]
  61. The United States Renal Data System: USRDS Annual Data Report, 1995
  62. Fumitake Gejyo Collaborate Study Group: The treatment of uraemic diabetic: Are we doing enough? A view from Japan. Nephrol Dial Transplant 10: 47-55,1995[Abstract/Free Full Text]
  63. Raine AE: A rising tide of diabetic nephropathy: The warning before the flood? Nephrol Dial Transplant 10:460 -461, 1995[Free Full Text]
  64. Ismail N, Becker B, Strzelczyk P, Ritz E: Renal disease and hypertension in non-insulin-dependent diabetes mellitus. Kidney Int 55: 1-28,1999[Medline]
  65. Morgensen CE, Christensen CK, Vittinghus E: The stages in diabetic renal disease: With emphasis on the stage of incipient diabetic nephropathy.Diabetes 32:64 -78, 1983
  66. Makino H: Glomerular extracellular matrix in glomerulosclerosis by molecular biology. Nippon Rinsho 50:3038 -3045, 1992[Medline]
  67. Caenazzo C, Garbisa S, Onisto M, Zampieri M, Baggio B, Gambaro G: Effect of glucose and heparin on mesangial alpha 1(IV)COLL and MMP-2/TIMP-2 mRNA expression. Nephrol Dial Transplant12 : 443-448,1997[Abstract/Free Full Text]
  68. Leehey DJ, Song RH, Alavi N, Singh AK: Decreased degradative enzymes in mesangial cells cultured in high glucose media.Diabetes 44:929 -935, 1995[Abstract]
  69. McLennan SV, Yue DK, Turtle JR: Effect of glucose on matrix metalloproteinase activity in mesangial cells. Nephron79 : 293-298,1998[Medline]
  70. Reckelhoff JF, Tygart VL, Mitias MM, Walcott JL: STZ-induced diabetes results in decreased activity of glomerular cathepsin and metalloprotease in rats. Diabetes 42:1425 -1432, 1993[Abstract]
  71. Reckelhoff JF, Tygart VL, Racusen LC, Dzielak DJ: Glomerular metalloprotease activity in streptozotocin-treated rats and in spontaneously diabetic rats (BB/DP). Life Sci 55:941 -950, 1994[Medline]
  72. Nakamura T, Fukui M, Ebihara I, Osada S, Tomino Y, Koide H: Abnormal gene expression of matrix metalloproteinases and their inhibitor in glomeruli from diabetic rats. Ren Physiol Biochem17 : 316-325,1994[Medline]
  73. Wu K, Setty S, Mauer SM, Killen P, Nagase H, Michael AF, Tsilibary EC: Altered kidney matrix gene expression in early stages of experimental diabetes. Acta Anat 158:155 -165, 1997[Medline]
  74. Suzuki D, Miyazaki M, Jinde K, Koji T, Yagame M, Endoh M, Nomoto Y, Sakai H: In situ hybridization studies of matrix metalloproteinase-3, tissue inhibitor of metalloproteinase-1 and type IV collagen in diabetic nephropathy.Kidney Int 52:111 -119, 1997[Medline]
  75. Del Prete D, Anglani F, Forino M, Ceol M, Fioretto P, Nosadini R, Baggio B, Gambaro G: Down-regulation of glomerular matrix metalloproteinase-2 gene in human NIDDM. Diabetologia 40:1449 -1454, 1997[Medline]
  76. Lupia E, Elliot SJ, Lenz O, Zheng F, Hattori M, Striker GE, Striker LJ: IGF-1 decreases collagen degradation in diabetic NOD mesangial cells: Implications for diabetic nephropathy. Diabetes40 : 1638-1644,1999
  77. Elliot SJ, Striker LJ, Hattori M, Yang CW, He CJ, Peten EP, Striker GE: Mesangial cells from diabetic NOD mice constitutively secrete increased amounts of insulin-like growth factor-I. Endocrinology133 : 1783-1788,1993[Abstract]
  78. Marti HP, Lee L, Kashgarian M, Lovett DH: Transforming growth factor-beta 1 stimulates glomerular mesangial cell synthesis of the 72-kd type IV collagenase. Am J Pathol 144:82 -94, 1994[Abstract]
  79. Cohen MP, Sharma K, Guo J, Eltayeb BO, Ziyadeh FN: The renal TGF-beta system in the db/db mouse model of diabetic nephropathy. Exp Nephrol 6: 226-233,1998[Medline]
  80. Sharma K, Ziyadeh FN: Hyperglycemia and diabetic kidney disease: The case for transforming growth factor-beta as a key mediator.Diabetes 44:1139 -1146, 1995[Abstract]
  81. Hoffman BB, Sharma K, Ziyadeh FN: Potential role of TGF-beta in diabetic nephropathy. Miner Electrolyte Metab24 : 190-196,1998[Medline]
  82. Mogyorosi A, Ziyadeh FN: Increased decorin mRNA in diabetic mouse kidney and in mesangial and tubular cells cultured in high glucose. Am J Physiol 275:F827 -F832, 1998[Abstract/Free Full Text]
  83. Kitamura M, Suto TS: TGF-beta and glomerulonephritis: Antiinflammatory versus prosclerotic actions. Nephrol Dial Transplant 12:669 -679, 1997[Abstract/Free Full Text]
  84. Salahudeen AK, Kanji V, Reckelhoff JF, Schmidt AM: Pathogenesis of diabetic nephropathy: A radical approach. Nephrol Dial Transplant 12:664 -668, 1997[Free Full Text]
  85. Mattana J, Margiloff L, Sharma P, Singhal PC: Oxidation of the mesangial matrix metalloproteinase-2 impairs gelatinolytic activity.Inflammation 22:269 -276, 1998[Medline]
  86. Craven PA, DeRubertis FR, Kagan VE, Melhem M, Studer RK: Effects of supplementation with vitamin C or E on albuminuria, glomerular TGF-ß, and glomerular size in diabetes. J Am Soc Nephrol8 : 1405-1414,1997[Abstract]
  87. Studer RK, Craven PA, DeRubertis FR: Antioxidant inhibition of protein kinase C signaled increases in transforming growth factor-beta in mesangial cells. Metabolism 46:918 -925, 1997[Medline]
  88. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977 -986, 1993[Abstract/Free Full Text]
  89. Schaefer L, Schaefer RM, Ling H, Teschner M, Heidland A: Renal proteinases and kidney hypertrophy in experimental diabetes.Diabetologia 37:567 -571, 1994[Medline]
  90. Singh AK, Mo W, Dunea G, Arruda JA: Effect of glycated proteins on the matrix of glomerular epithelial cells. J Am Soc Nephrol9 : 802-810,1998[Abstract]
  91. Mott JD, Khalifah RG, Nagase H, Shield CF, Hudson JK, Hudson BG: Nonenzymatic glycation of type IV collagen and matrix metalloproteinase susceptibility. Kidney Int 52:1302 -1312, 1997[Medline]
  92. Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M: Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 339: 69-75,1998[Abstract/Free Full Text]
  93. Lenz O, Zheng F, Vilar J, Doublier S, Lupia E, Schwedler S, Striker LJ, Striker GE: The inheritance of glomerulosclerosis in mice is controlled by multiple quantitative trait loci. Nephrol Dial Transplant13 : 3074-3078,1998[Abstract/Free Full Text]
  94. Nakamura T, Ebihara I, Tomino Y, Koide H: Effect of a specific endothelin A receptor antagonist on murine lupus nephritis. Kidney Int 47: 481-489,1995[Medline]
  95. Lovett DH, Johnson RJ, Marti HP, Martin J, Davies M, Couser WG: Structural characterization of the mesangial cell type IV collagenase and enhanced expression in a model of immune complex-mediated glomerulonephritis.Am J Pathol 141:85 -98, 1992[Abstract]
  96. Steinmann-Niggli K, Ziswiler R, Kung M, Marti HP: Inhibition of matrix metalloproteinases attenuates anti-Thy 1.1 nephritis. J Am Soc Nephrol 9: 397-407,1998[Abstract]
  97. McMillan JI, Riordan JW, Couser WG, Pollock AS, Lovett DH: Characterization of a glomerular epithelial cell metalloproteinase as matrix metalloproteinase-9 with enhanced expression in a model of membranous nephropathy. J Clin Invest 97:1094 -1101, 1996[Medline]
  98. Suto TS, Fine LG, Shimizu F, Kitamura M: In vivo transfer of engineered macrophages into the glomerulus: Endogenous TGF-ß-mediated defense against macrophage-induced glomerular cell activation. J Immunol 159:2476 -2483, 1997[Abstract/Free Full Text]
  99. Lefkowith JB: Leukocyte migration in immune complex glomerulonephritis: Role of adhesion receptors. Kidney Int51 : 1469-1475,1997[Medline]
  100. Harendza S, Behrens U, Zahner G, Schneider A, Stahl RA: In vitro characterization of the mesangial phenotype in a proliferative glomerulonephritis of the rat. Nephrol Dial Transplant12 : 2537-2541,1997[Abstract/Free Full Text]
  101. Akiyama K, Shikata K, Sugimoto H, Matsuda M, Shikata Y, Fujimoto N, Obata K, Matsui H, Makino H: Changes in serum concentrations of matrix metalloproteinases, tissue inhibitors of metalloproteinases and type IV collagen in patients with various types of glomerulonephritis. Res Commun Mol Pathol Pharmacol 95:115 -128, 1997[Medline]
  102. Koide H, Nakamura T, Ebihara I, Tomino Y: Increased mRNA expression of metalloproteinase-9 in peripheral blood monocytes from patients with immunoglobulin A nephropathy. Am J Kidney Dis28 : 32-39,1996[Medline]
  103. Nakamura T, Fukui M, Ebihara I, Tomino Y, Koide H: Low protein diet blunts the rise in glomerular gene expression in focal glomerulosclerosis.Kidney Int 45:1593 -1605, 1994[Medline]
  104. Goss KJ, Brown PD, Matrisian LM: Differing effects of endogenous and synthetic inhibitors of metalloproteinases on intestinal tumorigenesis.Int J Cancer 78:629 -635, 1998[Medline]
  105. Lombard MA, Wallace TL, Kubicek MF, Petzold GL, Mitchell MA, Hendges SK, Wilks JW: Synthetic matrix metalloproteinase inhibitors and tissue inhibitor of metalloproteinase (TIMP)-2, but not TIMP-1, inhibit shedding of tumor necrosis factor-alpha receptors in a human colon adenocarcinoma (Colo 205) cell line. Cancer Res 58:4001 -4007, 1998[Abstract/Free Full Text]
  106. Senatorski G, Paczek L, Sulowicz W, Gradowska L, Bartlomiejczyk I: Urine activity of cathepsin B, collagenase and urine excretion of TGF-beta 1 and fibronectin in membranous glomerulonephritis. Res Exp Med198 : 199-206,1998[Medline]
  107. Binder CJ, Weiher H, Exner M, Kerjaschki D: Glomerular overproduction of oxygen radicals in Mpv17 gene-inactivated mice causes podocyte foot process flattening and proteinuria: A model of steroid-resistant nephrosis sensitive to radical scavenger therapy. Am J Pathol154 : 1067-1075,1999[Abstract/Free Full Text]
  108. Reuter A, Nestl A, Zwacka RM, Tuckermann J, Waldherr R, Wagner EM, Hoyhtya M, Meyer GA, Angel P, Weiher H: Expression of the recessive glomerulosclerosis gene Mpv17 regulates MMP-2 expression in fibroblasts, the kidney, and the inner ear of mice. Mol Biol Cell9 : 1675-1682,1998[Abstract/Free Full Text]
  109. Weiher H, Noda T, Gray DA, Sharpe AH, Jaenisch R: Transgenic mouse model of kidney disease: Insertional inactivation of ubiquitously expressed gene leads to nephrotic syndrome. Cell62 : 425-434,1990[Medline]
  110. Orellana SA, Avner ED: Cell and molecular biology of kidney development. Semin Nephrol 18:233 -243, 1998[Medline]
  111. Lechner MS, Dressler GR: The molecular basis of embryonic kidney development. Mech Dev 62:105 -120, 1997[Medline]
  112. Dressler GR: Genetic control of kidney development. Adv Nephrol Necker Hosp 26:1 -17, 1997[Medline]
  113. Ganser GL, Stricklin GP, Matrisian LM: EGF and TGF alpha influence in vitro lung development by the induction of matrix-degrading metalloproteinases. Int J Dev Biol 35:453 -461, 1991[Medline]
  114. Sympson CJ, Talhouk RS, Alexander CM, Chin JR, Clift SM, Bissell MJ, Werb Z: Targeted expression of stromelysin-1 in mammary gland provides evidence for a role of proteinases in branching morphogenesis and the requirement for an intact basement membrane for tissue-specific gene expression. J Cell Biol 125:681 -693, 1994[Abstract/Free Full Text]
  115. Benaud C, Dickson RB, Thompson EW: Roles of the matrix metalloproteinases in mammary gland development and cancer. Breast Cancer Res Treat 50:97 -116, 1998[Medline]
  116. Tanney DC, Feng L, Pollock AS, Lovett DH: Regulated expression of matrix metalloproteinases and TIMP in nephrogenesis. Dev Dyn213 : 121-129,1998[Medline]
  117. Ota K, Stetler-Stevenson WG, Yang Q, Kumar A, Wada J, Kashihara N, Wallner EI, Kanwar YS: Cloning of murine membrane-type-1-matrix metalloproteinase (MT-1-MMP) and its metanephric developmental regulation with respect to MMP-2 and its inhibitor. Kidney Int54 : 131-142,1998[Medline]
  118. Kadono Y, Shibahara K, Namiki M, Watanabe Y, Seiki M, Sato H: Membrane type 1-matrix metalloproteinase is involved in the formation of hepatocyte growth factor/scatter factor-induced branching tubules in Madin-Darby canine kidney epithelial cells. Biochem Biophys Res Commun 251: 681-687,1998[Medline]
  119. Barasch J, Yang J, Qiao J, Tempst P, Erdjument-Bromage H, Leung W, Oliver JA: Tissue inhibitor of metalloproteinase-2 stimulates mesenchymal growth and regulates epithelial branching during morphogenesis of the rat metanephros. J Clin Invest 103:1299 -1307, 1999[Medline]
  120. Itoh T, Ikeda T, Gomi H, Nakao S, Suzuki T, Itohara S: Unaltered secretion of ß-amyloid precursor protein in gelatinase A (matrix metalloproteinase 2)-deficient mice. J Biol Chem272 : 22389-22392,1997[Abstract/Free Full Text]
  121. Sakurai H, Nigam SK: Transforming growth factor-beta selectively inhibits branching morphogenesis but not tubulogenesis. Am J Physiol 272:F139 -F146, 1997[Abstract/Free Full Text]
  122. Brenner BM, Chertow GM: Congenital oligonephropathy and the etiology of adult hypertension and progressive renal injury. Am J Kidney Dis 23:171 -175, 1994[Medline]
  123. Brenner BM, Anderson S: The interrelationships among filtration surface area, blood pressure, and chronic renal disease. J Cardiovasc Pharmacol 19[Suppl 6]:S1 -S7, 1992
  124. Zheng F, Striker GE, Esposito C, Lupia E, Striker LJ: Strain differences rather than hyperglycemia determine the severity of glomerulosclerosis in mice. Kidney Int54 : 1999-2007,1998[Medline]
  125. Lucas SR, Costa SV, Miraglia SM, Zaladek GF: Functional and morphometric evaluation of offspring kidney after intrauterine undernutrition.Pediatr Nephrol 11:719 -723, 1997[Medline]
  126. Gilbert T, Cibert C, Moreau E, Geraud G, Merlet-Benichou C: Early defect in branching morphogenesis of the ureteric bud in induced nephron deficit. Kidney Int 50:783 -795, 1996[Medline]
Received for publication July 12, 1999. Accepted for publication October 9, 1999.




This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
M. Wornle, M. Roeder, M. Sauter, and A. Ribeiro
Role of matrix metalloproteinases in viral-associated glomerulonephritis
Nephrol. Dial. Transplant., November 12, 2008; (2008) gfn627v1.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. K. Glassberg, S. J. Elliot, J. Fritz, P. Catanuto, M. Potier, R. Donahue, W. Stetler-Stevenson, and M. Karl
Activation of the Estrogen Receptor Contributes to the Progression of Pulmonary Lymphangioleiomyomatosis via Matrix Metalloproteinase-Induced Cell Invasiveness
J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1625 - 1633.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
Y. Li, Y. S. Kang, C. Dai, L. P. Kiss, X. Wen, and Y. Liu
Epithelial-to-Mesenchymal Transition Is a Potential Pathway Leading to Podocyte Dysfunction and Proteinuria
Am. J. Pathol., February 1, 2008; 172(2): 299 - 308.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
E. Sanchez-Lopez, J. Rodriguez-Vita, C. Cartier, M. Ruperez, V. Esteban, G. Carvajal, R. Rodrigues-Diez, J. J. Plaza, J. Egido, and M. Ruiz-Ortega
Inhibitory effect of interleukin-1 on angiotensin II-induced connective tissue growth factor and type IV collagen production in cultured mesangial cells
Am J Physiol Renal Physiol, January 1, 2008; 294(1): F149 - F160.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
J.-S. F. Sanders, M. G. Huitema, R. Hanemaaijer, H. van Goor, C. G. M. Kallenberg, and C. A. Stegeman
Urinary matrix metalloproteinases reflect renal damage in anti-neutrophil cytoplasm autoantibody-associated vasculitis
Am J Physiol Renal Physiol, December 1, 2007; 293(6): F1927 - F1934.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
B. Bauvois, N. Mothu, J. Nguyen, T. Nguyen-Khoa, L.-H. Noel, and P. Jungers
Specific changes in plasma concentrations of matrix metalloproteinase-2 and -9, TIMP-1 and TGF-{beta}1 in patients with distinct types of primary glomerulonephritis
Nephrol. Dial. Transplant., April 1, 2007; 22(4): 1115 - 1122.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
M. E. Marin-Castano, G. E. Striker, O. Alcazar, P. Catanuto, D. G. Espinosa-Heidmann, and S. W. Cousins
Repetitive Nonlethal Oxidant Injury to Retinal Pigment Epithelium Decreased Extracellular Matrix Turnover In Vitro and Induced Sub-RPE Deposits In Vivo.
Invest. Ophthalmol. Vis. Sci., September 1, 2006; 47(9): 4098 - 4112.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
Y. V. Mukhin, M. Gooz, J. R. Raymond, and M. N. Garnovskaya
Collagenase-2 and -3 Mediate Epidermal Growth Factor Receptor Transactivation by Bradykinin B2 Receptor in Kidney Cells
J. Pharmacol. Exp. Ther., September 1, 2006; 318(3): 1033 - 1043.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
H.-A. Shui, S.-M. Ka, J.-C. Lin, J.-H. Lee, J.-S. Jin, Y.-F. Lin, L.-F. Sheu, and A. Chen
Fibronectin in blood invokes the development of focal segmental glomerulosclerosis in mouse model
Nephrol. Dial. Transplant., July 1, 2006; 21(7): 1794 - 1802.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. Bolbrinker, S. Markovic, M. Wehland, W. B. W. H. Melenhorst, H. van Goor, and R. Kreutz
Expression and Response to Angiotensin-Converting Enzyme Inhibition of Matrix Metalloproteinases 2 and 9 in Renal Glomerular Damage in Young Transgenic Rats with Renin-Dependent Hypertension
J. Pharmacol. Exp. Ther., January 1, 2006; 316(1): 8 - 16.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
J. J.T.H. Roelofs, K. M.A. Rouschop, J. C. Leemans, N. Claessen, A. M. de Boer, W. M. Frederiks, H.R. Lijnen, J. J. Weening, and S. Florquin
Tissue-Type Plasminogen Activator Modulates Inflammatory Responses and Renal Function in Ischemia Reperfusion Injury
J. Am. Soc. Nephrol., January 1, 2006; 17(1): 131 - 140.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
T. Naito, Y. Tanihata, H. Nishimura, T. Tanaka, C. Higuchi, T. Taguchi, and T. Sanaka
Expression of matrix metalloproteinase-9 associated with ets-1 proto-oncogene in rat tubulointerstitial cells
Nephrol. Dial. Transplant., November 1, 2005; 20(11): 2333 - 2348.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
T. McMorrow, M. M. Gaffney, C. Slattery, E. Campbell, and M. P. Ryan
Cyclosporine A induced epithelial-mesenchymal transition in human renal proximal tubular epithelial cells
Nephrol. Dial. Transplant., October 1, 2005; 20(10): 2215 - 2225.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
A. R. Chade, O. P. Mushin, X. Zhu, M. Rodriguez-Porcel, J. P. Grande, S. C. Textor, A. Lerman, and L. O. Lerman
Pathways of Renal Fibrosis and Modulation of Matrix Turnover in Experimental Hypercholesterolemia
Hypertension, October 1, 2005; 46(4): 772 - 779.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
L.-J. Ma, S. Nakamura, J. C. Aldigier, M. Rossini, H. Yang, X. Liang, I. Nakamura, C. Marcantoni, and A. B. Fogo
Regression of Glomerulosclerosis with High-Dose Angiotensin Inhibition Is Linked to Decreased Plasminogen Activator Inhibitor-1
J. Am. Soc. Nephrol., April 1, 2005; 16(4): 966 - 976.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
S. Zafiriou, S. R. Stanners, S. Saad, T. S. Polhill, P. Poronnik, and C. A. Pollock
Pioglitazone Inhibits Cell Growth and Reduces Matrix Production in Human Kidney Fibroblasts
J. Am. Soc. Nephrol., March 1, 2005; 16(3): 638 - 645.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
M. Karl, M. Potier, I. H. Schulman, A. Rivera, H. Werner, A. Fornoni, and S. J. Elliot
Autocrine Activation of the Local Insulin-Like Growth Factor I System Is Up-Regulated by Estrogen Receptor (ER)-Independent Estrogen Actions and Accounts for Decreased ER Expression in Type 2 Diabetic Mesangial Cells
Endocrinology, February 1, 2005; 146(2): 889 - 900.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
J.-S. F. Sanders, H. van Goor, R. Hanemaaijer, C. G. M. Kallenberg, and C. A. Stegeman
Renal expression of matrix metalloproteinases in human ANCA-associated glomerulonephritis
Nephrol. Dial. Transplant., June 1, 2004; 19(6): 1412 - 1419.
[Abstract] [Full Text] [PDF]

Home page